FDA investigation outcome for Systane contamination by June 2025?
Manufacturing defect • 25%
Supply chain contamination • 25%
No specific cause identified • 25%
Other cause • 25%
FDA investigation results or public statements
Alcon Recalls One Lot of Systane Eye Drops Nationwide Due to Fungal Contamination, FDA Warns of Vision-Threatening Risks
Dec 26, 2024, 07:01 PM
Systane brand eye drops have been recalled nationwide due to possible fungal contamination, according to an announcement from the Food and Drug Administration (FDA). The recall affects one lot of Systane Lubricant Eye Drops Ultra PF, Single Vials On-the-Go, after a consumer reported finding a foreign material in a sealed vial. Upon investigation, the Texas-based manufacturer, Alcon, confirmed that the material was fungal in nature. The FDA has warned that this contamination could lead to eye infections that may threaten vision, particularly in immunocompromised individuals. The recalled eye drops are commonly used for temporary relief of burning and irritation associated with dry eye symptoms and are sold at retailers including Publix and Amazon. Consumers are advised to check their medicine cabinets for the affected product.
View original story
Major compliance issues • 25%
Recall expanded • 25%
Minor compliance issues • 25%
No issues found • 25%
Discontinue product • 25%
Product reformulation • 25%
Increased quality checks • 25%
No significant changes • 25%
No significant change • 25%
Decreased trust in Alcon • 25%
Switch to alternative brands • 25%
Increased demand for safer packaging • 25%
Mandatory product reformulation • 25%
Temporary production halt • 25%
No further action • 25%
Fine imposed • 25%
Other • 25%
Target • 25%
CVS • 25%
Walgreens • 25%
Investigation inconclusive • 25%
No significant contamination found • 25%
Contamination confirmed, no recall • 25%
Contamination confirmed, recall issued • 25%
No action taken • 25%
Investigation initiated • 25%
Recall issued • 25%
Warning issued • 25%
Increase by more than 10% • 25%
Decrease by more than 10% • 25%
No significant change (+/- 10%) • 25%
Other outcome • 25%